• Looking to the future: immune regulation not suppression

  • Looking to the future: immune regulation not suppression

  • Looking to the future: immune regulation not suppression

#Transplant Immunology #Europe

Live Session:

Friday, August 13, 2021 - 12:00 PM (Local time in Frankfurt)
Local time (Corresponding local time at your current location)

Join us:

Add to your Calendar


TTS Members can register for FREE!


This masterclass will present the state-of-the-art in immune regulatory therapies, with a particular focus on cellular therapies which are undergoing clinical evaluation.

Learning Objectives:

  • Learn latest advances in next-generation regulatory cell therapies to induce tolerance in solid organ transplantation

  • Gain knowledge in the current status of the various clinical trials in this field worldwide

Accreditation Statement

“This Masterclass has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

Attendance to the live Masterclass and the completion of the post-event survey are mandatory to receive the certificate and CME credits.

“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”


Are all cell therapies created equal?

Edward K. Geissler

Head of Experimental Surgery
Department of Surgery
University Hospital Regensburg
Regensburg, Germany

Ed Geissler is a scientist at the University of Regensburg working in different areas spanning the field of Transplantation including basic immunology and tolerance, solid organ transplantation, immunosuppressive therapies and post-transplant malignancy. He has focussed on the understanding and prevention of immunologic rejection of transplanted organs and on novel, as well as conventional, immunosuppressive therapies to prevent transplant rejection. He also has an interest in post-transplant development of cancer, and has made a strong translational research effort through molecular targeting to reduce the threat of malignancies in transplant recipients. In another effort to reduce the burden of immunosuppressive drugs, he is leading an initiative to introduce cellular therapy in transplant recipients. Transfer of new ideas from the basic research lab to the transplant recipient is a central theme of his work. 

The promise of IL-2 therapy in transplantation

Alberto Sanchez Fueyo

Professor of Hepatology, Department of Inflammation Biology
Academic Director of the Institute of Liver Studies
King’s College London
London, UK

Prof. Sánchez-Fueyo received his MD from the University of Barcelona in 1993 and trained in Gastroenterology & Hepatology at Hospital Clinic Barcelona. He conducted post-doctoral research in Transplant Immunology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston, USA) and was a faculty member at the Liver Transplant Unit at the Hospital Clinic Barcelona/IDIBAPS (University of Barcelona), where he directed the Liver Transplant Immunology Lab from 2004 to 2012. Prof. A. Sánchez-Fueyo joined King’s College London as Head of the Liver Sciences Department in 2012. His research is focused on understanding the mechanisms responsible for immunological tolerance in transplantation and developing novel immunotherapies in liver diseases.


Petra Reinke

Berlin Center for Advanced Therapies (BeCAT),
Director BIH Center for Regenerative Therapies (BCRT),
Head of research area “immune system”,
Head of GMP-Facility
Charité - Universitätsmedizin Berlin
Berlin, Germany

Fadi Issa

Associate Professor, Nuffield Department of Surgical Sciences
University of Oxford
Oxford, UK

Schedule (90 min):

  • 05 min

    Welcome and introduction by the Chairs

  • 25 min

    Presentation: Are all cell therapies created equal? Edward K. Geissler, Germany

  • 05 min

    Live Q&A with Edward K. Geissler, Germany

  • 25 min

    Presentation: The promise of IL-2 therapy in transplantation, Alberto Sanchez Fueyo, UK

  • 05 min

    Live Q&A with Alberto Sanchez Fueyo, UK

  • 20 min

    Interactive panel discussion with audience participation led by the Chairs

  • 05 min

    Masterclass closing remarks

Join Our Mailing List

Ask a Question

Masterclass Prospectus Request